TD Cowen initiated a $24 price target for Roivant Sciences (ROIV) following the release of its announcement that its Brepo 30mg dose succeeded in Ph3 VALOR DM with robust and consistent statistical signifiant efficacy on all key endpoints.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences price target raised to $20 from $18 at Jefferies
- Roivant Sciences price target raised to $21 from $15 at Guggenheim
- Roivant Sciences price target raised to $20 from $16 at JPMorgan
- Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright
- Yaron Werber’s Buy Rating Highlights Brepocitinib’s Potential as a Leading Treatment for Dermatomyositis